Cost-effectiveness analysis based on two models of sacituzumab tirumotecan versus platinum-based chemotherapy as second-line treatment in EGFR-mutant non-small-cell lung cancer.
Jin L; Han L; Zeng J · 2026 · Frontiers in public health
WASTE classifies this as Methods Dead-End · AI classification, approximate
A method or design hit a limitation — check whether the same constraint applies to your setup.
Abstract (excerpt)
Background For patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC) who progress after first-line therapy, effective subsequent options are urgently needed. From the perspective of China's healthcare system, this study…
Excerpt shown for reference under fair use — read the full paper at the publisher.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke
Negative / Null Result ReportDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
Negative / Null Result ReportStenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis
Negative / Null Result ReportEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Replication FailureA Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Negative / Null Result ReportSpironolactone for Heart Failure with Preserved Ejection Fraction
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: Europe PMC · DOI 10.3389/fpubh.2026.1802471